At the World Health Summit in Berlin on October 13, 2026, the Bill & Melinda Gates Foundation together with Wellcome announced a landmark $100 million joint commitment dedicated to drastically reducing global stillbirth rates over the next decade. The major global health funding initiative aims to accelerate clinical research, scale up access to low-cost diagnostic technologies, and deploy modernized fetal monitoring tools in low- and middle-income countries. According to international healthcare experts participating in the summit, nearly two million stillbirths occur annually worldwide, with a vast majority occurring during labor and childbirth due to preventable complications such as placental insufficiency, undetected fetal distress, and maternal infections. The new financial grant will support research institutions and regional healthcare providers in developing non-invasive point-of-care devices, enhancing emergency obstetric care training for midwives, and expanding early-stage prenatal screening protocols across underserved community health centers. Public health leaders and maternal welfare advocates praised the pledge, noting that integrating advanced diagnostic innovations into primary maternal care infrastructure offers an unprecedented opportunity to safeguard infant lives and reduce preventable childbirth fatalities globally.

Targeting an Overlooked Global Public Health Crisis

Addressing one of the most persistent and neglected challenges in global maternal-child health, the Bill & Melinda Gates Foundation and Wellcome Leap pledged a combined $100 million toward a flagship research and deployment initiative. Each organization is committing $50 million to establish the Uzima program, designed to generate evidence, scale clinical innovations, and halve stillbirth rates in targeted countries over the coming decade.

Globally, nearly 2 million babies are stillborn each year, with almost 50% of cases occurring across sub-Saharan Africa due to limited access to real-time fetal monitoring, delayed risk identification, and inadequate intrapartum care.

Overview: Key Parameters of the Uzima Stillbirth Initiative

Operational / Strategic ParameterOfficial Specifications & Commitments
Funding PartnersGates Foundation ($50M) & Wellcome Leap ($50M)
Program NameUzima (Swahili for "Fullness of Life" / Vitality)
Initial Target FocusSub-Saharan Africa (High-burden, low-resource health settings)
Core Decade GoalCut stillbirth rates by 50% in selected partner nations
Primary Launch VenueWorld Health Summit 2026 (Berlin, Germany)

AI Decision Support and Advanced Point-of-Care Diagnostics

The initial three-year phase of Uzima focuses on building and field-testing accessible technologies that equip frontline midwives and community health workers to detect fetal distress and maternal complications well before delivery.

Uzima Strategic Innovation Pipeline: ----------------------------------- Early Fetal Distress Detection ──> AI-Enabled Decision Support Tools ──> Point-of-Care Triage ──> Timely Clinical Action & 50% Rate Reduction

Key technological pillars prioritized under the program include:

  1. AI-Enabled Decision Support Systems: Software algorithms designed to assist healthcare workers in interpreting warning signs—such as abnormal heart rate patterns and placental dysfunction—and taking timely clinical action.

  2. Integrated Patient Navigation: Digital platforms that track progress, synthesize maternal data, and guide mothers through antenatal care pathways.

  3. Low-Cost Fetal & Intrapartum Monitoring: Non-invasive, portable diagnostic equipment built specifically for rural clinics lacking surgical infrastructure.

Country-Led Co-Design and Scalable Blueprints

Leaders from both foundations emphasized that participating health ministries across sub-Saharan Africa will co-design research protocols to ensure solutions align directly with local healthcare infrastructure.

By developing a validated blueprint for stillbirth prevention in low-resource environments, Uzima aims to attract additional philanthropic and sovereign co-investors, expanding the technology stack across Latin America and South Asia in subsequent phases.